Dynavax, Merck deal

The companies partnered to evaluate product combinations for clinical testing. Merck will sponsor and fund a Phase I trial of Dynavax’s SD-101 in combination with Merck’s MK-1966 to treat solid or hematological malignancies. Dynavax will sponsor and fund a Phase Ib/II trial of SD-101 in combination with Merck’s cancer drug Keytruda pembrolizumab to treat advanced melanoma. Both trials are slated to begin next half. The parties have an option to extend either combination to include Phase III testing. ...